Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses Versus Investigator`s Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies

Trial Profile

Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses Versus Investigator`s Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Futuximab/modotuximab (Primary) ; Capecitabine; Fluorouracil
  • Indications Colorectal cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors EMD Serono; Merck KGaA; Symphogen
  • Most Recent Events

    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results (n=193) assessing efficacy of futuximab versus best supportive care or capecitabine or 5-fluorouracil in patients with metastatic colorectal cancer and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, were presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Status changed from active, no longer recruiting to completed, according to results presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top